It is worth noting that potential off-target effects of HUWE1 inhibition warrant caution in clinical trial design—as hematopoietic-specific HUWE1 knockout results in bone marrow failure in murine models (King et al., 2016). This evidence concerns the gene HUWE1 and Bone marrow hypocellularity.